Theraclion SA

MUN:941 Stock Report

Market Cap: €16.8m

Theraclion Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Martin Deterre

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure1.5yrs
CEO ownershipn/a
Management average tenure1.2yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

CEO

Martin Deterre

1.5yrs

Tenure

Mr. Martin Deterre is Chief Executive Officer of Theraclion SA from May 2023. He was Director of Engineering and Development of Theraclion since 2020. He has successfully led the development of the new gen...

Leadership Team

NamePositionTenureCompensationOwnership
Yann Duchesne
Executive Chairman2.8yrs€472.00kno data
Martin Deterre
Chief Executive Officer1.5yrsno datano data
Christophe Lamboeuf
Chief Financial Officerless than a yearno datano data
Gaylord Tallec
Vice President of Operations2.8yrsno datano data
Jérémie Anquez
VP Research & Chief Scientific Officerless than a yearno datano data
Jose Abellan-Martinez
Vice President of Sales & Business Developmentno datano datano data
Marie Berne
Marketing & Customer Relations Directorless than a yearno datano data
Michel Nuta
VP of Veins & Chief Medical Officerno datano datano data

1.2yrs

Average Tenure

Experienced Management: 941's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Yann Duchesne
Executive Chairman2.8yrs€472.00kno data
Ari Kellen
Independent Director5.6yrsno datano data
Claude Lenoir
Member of the Board1.8yrsno datano data
Shawn Langer
Independent Director5.6yrsno datano data
Mehdi Glaoui
Director3.4yrsno datano data
Cedric Bellanger
Director2.8yrsno datano data
Lijuan Deng
Member of the Board1.8yrsno datano data

2.8yrs

Average Tenure

Experienced Board: 941's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.